CTLA4 and nasopharyngeal carcinoma: However, the recently reported clinical trial of anti-CTLA-4 and anti-PD-L1 combination therapy in R/M NPC demonstrated an unsatisfactory results, with 38% objective response rate (ORR) and 5.9 months median duration of response (mDoR)11.